Provided by Tiger Trade Technology Pte. Ltd.

Allogene Therapeutics Inc.

1.74
+0.01000.58%
Volume:3.28M
Turnover:5.68M
Market Cap:600.30M
PE:-2.67
High:1.76
Open:1.73
Low:1.70
Close:1.73
52wk High:4.46
52wk Low:1.04
Shares:345.00M
Float Shares:262.00M
Volume Ratio:0.77
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6510
EPS(LYR):-0.8652
ROE:-42.39%
ROA:-22.08%
PB:1.38
PE(LYR):-2.01

Loading ...

Allogene Therapeutics Up Over 36%, on Track for Highest Close Since April 2024 -- Data Talk

Dow Jones
·
Apr 13

Allogene Therapeutics Reports Interim Trial Results For Lymphoma Therapy

MT Newswires Live
·
Apr 13

Allogene Shares Gain on Interim Data From Lymphoma-Treatment Trial

Dow Jones
·
Apr 13

Allogene Therapeutics Shares Rise 70% Premarket After Co's Blood Cancer Therapy Delays Cancer Relapse in Mid-Stage Study

THOMSON REUTERS
·
Apr 13

Allogene's blood cancer therapy delays cancer relapse in mid-stage study

Reuters
·
Apr 13

Allogene ALPHA3 interim analysis shows 58.3% MRD clearance with cema-cel in LBCL

Reuters
·
Apr 13

Allogene Therapeutics Inc: No Hospitalizations for Treatment-Related Adverse Events

THOMSON REUTERS
·
Apr 13

Allogene Therapeutics Reports Interim Futility Analysis From Pivotal Alpha3 Trial Showing 58.3% Mrd Clearance With Cemacabtagene Ansegedleucel (Cema-Cel) VS. 16.7% in Observation Arm in First-Line Consolidation Lbcl

THOMSON REUTERS
·
Apr 13

Allogene Therapeutics Inc - Enrollment Expected to Complete by Year-End 2027; Interim Efs Analysis in Mid-2027

THOMSON REUTERS
·
Apr 13

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM

Reuters
·
Apr 13

Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Takeda Pharmaceutical Company (TAK)

TIPRANKS
·
Mar 31

Allogene Therapeutics Faces Trial Setback as ALLO-647 Halt Raises Lymphodepletion and Regulatory Timeline Risks

TIPRANKS
·
Mar 14

Allogene Therapeutics (ALLO) Gets a Buy from Piper Sandler

TIPRANKS
·
Mar 13

REFILE-Allogene Therapeutics Q4 net loss narrows

Reuters
·
Mar 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 11

Allogene Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
Mar 11

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 09